Notes
The study was affiliated with, and funded by, Pfizer.
Reference
, et al. Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden. PharmacoEconomics-Open : 29 Jul 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00287-2
Rights and permissions
About this article
Cite this article
Inotuzumab ozogamicin cost effective for acute lymphoblastic leukaemia in Sweden and Norway. PharmacoEcon Outcomes News 884, 18 (2021). https://doi.org/10.1007/s40274-021-7925-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7925-3